RNS Number : 7357N
Life Settlement Assets PLC
27 September 2023
 

LIFE SETTLEMENT ASSETS PLC

 

LEI: 2138003OL2VBXWG1BZ27

 

(the "Company" or "LSA")

 

Half-Year Announcement

 

LSA, a closed-ended investment company which manages portfolios of whole and fractional interests in life settlement policies issued by life insurance companies operating predominantly in the United States, is pleased to announce its unaudited half-year results for the period ended 30 June 2023.

 

Highlights

·    Total maturities during the period were USD $14.2 million (H1 2022 USD $16.3 million)

·    Estimated AE ratio ("actual to expected ratio") of HIV segment of 80%, and of non-HIV segment of 147%, aggregating to 119%

·    The Company's Net Asset Value ("NAV") as at 30 June 2023 was $USD 2.16 per share

·    Cost reductions continue to be a strategic priority.

 

Michael Baines, Chairman, commented:

"While these results cover a period when market fears of stagflation are accompanied by inflation and rising interest rates, the non-correlation of our performance with financial markets works in favour of our investment case. It is worth noting the outperformance of the portfolio when measured against other long duration fixed income assets over the last two years.

 

The non-HIV policy component of the portfolio has experienced a high level of maturities, while the HIV policy component had somewhat less.  On an aggregated basis, this has meant higher than expected cash receipts, but with maturities closely reflecting their book values, NAV has not been materially affected.

 

With the completion of the acquisition and the current assimilation of the acquired policies into the portfolio, the Board remains focussed on assessing the mortality risk in the Company's portfolio.  Alongside continuing to make further distributions when maturities occur, controlling costs against the background of the inflationary environment remains a core priority for the Board."

 

Enquiries

For further information, please visit https://www.lsaplc.com/, or contact:

 

Acheron Capital Limited (Investment Manager)

Jean-Michel Paul

020 7258 5990

 

Shore Capital (Financial Adviser and Broker)

Robert Finlay

020 7408 4080

 

ISCA Administration Services Limited

Company Secretary

Tel: 01392 487056

 

Company performance

 

Performance analysis is provided in the tables below:

A Share Class


As at

30 June

 2023

As at

31 December

 2022

Percentage

Change

(%)

Net assets attributable to Shareholders (USD '000)

 

107,776 

 

109,913 

 

(1.9)

Shares in issue

49,826,784 

49,826,784 

-  

NAV per share (USD)

2.16 

2.21 

(1.9)

Closing share price (USD)

1.56 

1.37 

13.9 

(Discount) to NAV (%)

(27.9)

(38.0)

10.1 


  Period ended

30 June 

2023 

  Period ended

30 June 

2022 

Percentage

Change

(%)

 

Total maturities (USD '000)

14,190 

16,266 

(12.8)

 

Net income from portfolio (USD '000)

5,446 

4,892 

11.3 

 

Profit for the period (USD '000)

864 

101 

7.6 

 

 

Chairman's Statement

On behalf of the Board, I am pleased to present the Company's half year results for the period ended 30 June 2023.

 

These results cover a period when market fears of stagflation are accompanied by inflation and rising interest rates. Positively for the Company, the non-correlation of our performance with financial markets works in favour of our investment case.  In this context it is worth noting the outperformance of the portfolio when measured against other long duration fixed income assets over the last two years.

 

Investment overview

The financial highlights above show the results for the half year to 30 June 2023.  As investors are aware, in the first half of 2023 the acquisition of the MBC portfolio of insurance policies in the MBC Trust was completed.  However, the Company still awaits confirmation of the final distribution by MBC to its investors, including APT.  Confirmation of the value of the portfolio was conducted by the Company's external actuary, and this value has been incorporated into the estimated NAV as at 30 June 2023.

 

The Company's portfolio has experienced a number of sizeable maturities in the period, with an aggregate value of USD 14.2 million arising from a total of 51 policies.   

 

Policy administration costs are a key component in determining the future returns available on the Company's portfolio and Acheron, continues its review of the policy administration cost base. Whilst the Company's portfolio structure has been somewhat simplified following the MBC acquisition, the overall cost of holding life settlements has, nevertheless, been increasing due to inflationary pressures on all market participants.

 

The Life Settlement Market

The secondary market in life settlements continues to be active, with the decorrelation of the asset class (especially in US dollars) attracting investors in search of a safe haven.

 

Portfolio

The overall portfolio is subdivided into portfolios exposed to either HIV-positive policy holders or non-HIV positive policy holders. The following table provides information on the Company's policies by exposure to HIV and non-HIV positive insureds as at 30 June 2023.

 

Share Class A

HIV

Non-HIV

Total

Number of policies

4 214

129

4 343

Total gross face value

413 951 446

83 568 597

497 520 043

Valuation

51 338 880

22 081 700

73 420 580

Percentage of face

12.4%

26.4%

14.8%

 

The non-HIV policy component of the portfolio has experienced a high level of maturities, while the HIV policy component had somewhat less.  On an aggregated basis, this has meant higher than expected cash receipts, but with maturities closely reflecting their book values, NAV has not been materially affected.

 

Maturities in the period up to 30 June 2023 are shown in the table below.

 


Class A

HIV Maturities (USD)

4 014 946

Non-HIV Maturities (USD)

10 175 040

Total Maturities (USD)

14 189 986

 

In the period under review the non-HIV segment of the portfolio experienced an estimated AE ("Actual to Expected") ratio of 147%.  However, the HIV segment of the portfolio had an estimated AE ratio of 80%. While the Non-HIV portfolio has performed well above expectations, the HIV portfolio has underperformed against expectation during the first half year. 

 

AE*

All classes

HIV

80%

Non-HIV

147%

Total

119%

 

* in maturity dollar amounts, estimated until June 2023.

 

The Board believes results over the long term are the best indicator of underlying performance, and it will continue to monitor performance in the second half to ascertain whether model assumptions remain accurate.

 

On 30 June 2023, Share Class A had a NAV of USD 2.1630 per share with the NAV performance history shown in the table below.

 

Class A

Year

Jan

Feb

Mar

April

May

Jun

YTD

Total NAV Return

2023

3.87%

-0.85%

-1.19%

1.33%

-1.01%

-1.33%

0.78%

 

Portfolio Composition

Further information on the composition of the portfolio as at 30 June 2023 can be found in the Factsheet on our website https://www.lsaplc.com/investor-relations/announcements/.

 

Distributions

On 3 February 2023 the Company declared a special dividend of 6.0209 cents per share totalling approximately USD3.0 million, which was paid on 24 February 2023 to Shareholders on the register on 10 February 2023.  The Board anticipates being in a position to make further distributions following receipt of the MBC proceeds, and, in the meantime, Acheron will be evaluating the future potential cashflows from the portfolio in the light of its work on reviewing administration costs.

 

Outlook

With the completion of the acquisition and the current assimilation of the acquired policies into the portfolio, the Board remains focussed on assessing the mortality risk in the Company's portfolio.  Alongside continuing to make further distributions when maturities occur, controlling costs against the background of the inflationary environment remains a core priority for the Board.  At the same time the Board will continue to promote awareness of the relative benefits to investors of the Company's investment case.

 

Michael Baines

Chairman

26 September 2023

 

Key Performance Indicators (KPIs)

 

The Board monitors success in implementing the Company's strategy against a range of key performance indicators (KPIs), which are viewed as significant measures of success over the longer term. These key indicators are those provided in the performance tables above. Although performance relative to the KPIs is monitored over quarterly periods, it is success over the long-term that is viewed as more important. This is particularly important given the inherent volatility of maturities and short-term investment returns.

 

The Board has adopted the following KPIs:

 

·      Share Price - a key measure for Shareholders to show the most likely realisable value of this investment if it was sold. Changes in the share price are closely monitored by the Board.

 

·      NAV per share - as this is the primary indicator of the underlying value attributable to each share.

 

·      Premium/(discount) to NAV - as this measure can be used to monitor the difference between the underlying Net Asset Value and share price.

 

·      Total maturities (USD) - the value of the total maturities in USD provides an indicator of the underlying cash flow that the Company receives from its main source of income - policy maturities. There are factors which could impact the outcome of this performance measure including: average life expectancy and the age of the underlying policy holders. Please note that the Actual to Expected ("A/E") ratio, which is closely linked to the total maturities KPI, is a key method by which the Board monitors the level of maturities. The A/E ratio measures the declared maturities compared to the projected maturities based on the actuarial models.  A ratio close to 100% indicates maturities correspond exactly to the model. A percentage greater than 100% means the maturities are more than anticipated by the models and less than 100% the opposite is the case.

 

·      Earnings per share - this is a key measure of financial performance used to assess the fortunes of the Company over each financial period.

 

·      Profit/(loss) for the period - this is a key measure of financial performance used to assess the fortunes of the Company over each financial period.

 

·      Running costs - The Ongoing Charges of the Company for the financial period under review represented 5.0% (year to 31 December 2022: 7.1%) of average net assets. Excluding the servicing and legal costs the ratio would be 2.5%.

 

Shareholders should note that this ratio has been calculated in accordance with the Association of Investment Companies' ("AIC") recommended methodology, published in May 2012. This figure indicates the annual percentage reduction in Shareholder returns as a result of recurring operational expenses. Although the Ongoing Charges figure is based on historic information, it does provide Shareholders with a guide to the level of costs that may be incurred by the Company in the future.

 

Please Note: The Company regularly uses alternative performance measures to present its financial performance.  These measures may not be comparable to similar measures used by other companies, nor do they correspond to IFRS standards or other accounting principles.

 

Directors' Statement of Principal Risks and Uncertainties

 

The important events that have occurred during the period under review and the key factors influencing the financial statements are set out in the Chairman's Statement above.

           

In accordance with DTR 4.2.7, the Directors consider that the principal risks and uncertainties facing the Company have not materially changed since the publication of the Annual Report and Accounts for the year ended 31 December 2022.

 

The principal risks faced by the Company include, but are not limited to:

 

·    HIV Mortality risk

·    Premium management risk

·    Volatility risk

·    Fractional premium risk

·    Fractional ownership risk

·    Advance age mortality risk

·    Discount rate risk

·    Modelling risk

·    Tax

·    Breach of applicable legislative obligations

·    Counterparty risk

 

A more detailed explanation of these risks and the way in which they are managed can be found in the Strategic Report on pages 21 to 23 and in Note 4 to the Financial Statements on pages 63 to 66 of the 2022 Annual Report and Accounts - copies can be found via the Company's website, www.lsaplc.com.

 

There have been no significant changes in the related party disclosures set out in the Annual Report.

 

Directors' Statement of Responsibilities in Respect of the Financial Statements

In accordance with Disclosure and Transparency Rule (DTR) 4.2.10 Michael Baines (Chairman), Christopher Casey (Audit Committee Chairman) and Guner Turkmen, the Directors, confirm that to the best of their knowledge:

 

·    The condensed set of financial statements contained within this Half-Yearly financial report have been prepared in accordance with International Accounting Standard ("IAS") 34 as adopted in the UK and gives a true and fair view of the assets, liabilities, financial position and profit of the Company; and

 

·    The Half-Yearly financial report includes a fair review of the information required by the FCA's Disclosure and Transparency Rule 4.2.7R being disclosure of important events that have occurred during the first six months of the financial year, their impact on the condensed set of financial statements and a description of the principal risks and uncertainties for the remaining six months of the year; and

 

·    The Half Yearly financial report includes a fair review of the information required by the FCA's Disclosure and Transparency Rule 4.2.8R being disclosure of related party transactions during the first six months of the financial year, how they have materially affected the financial position of the Company during the period and any changes therein.

 

This Half-Yearly Report was approved by the Board of Directors on 26 September 2023 and the above responsibility statement was signed on its behalf by:

 

Michael Baines

Chairman

26 September 2023

 

Condensed Statement of Comprehensive Income

for the six months ended 30 June 2023

______________________________________________



Six months ended

30 June 2023

Six months ended

 30 June 2022

Year ended

31 December 2022



(unaudited)

(unaudited)

(audited)


Note

Revenue

Capital

Total

Revenue

Capital

Total

Revenue

Capital

Total



USD'000

USD'000

USD'000

USD'000

USD'000

USD'000

USD'000

USD'000

USD'000

Income






















Gains from life settlement portfolios

3










Maturities


14,190 

14,190 

16,266 

16,266 

27,197 

27,197 

Acquisition cost of maturities and fair value movement


 

 

(4,213)

 

(4,213)

 

 

(3,644)

 

(3,644)

 

 

(10,220)

 

(10,220)

Sub total


9,977 

9,977 

12,622 

12,622 

16,977 

16,977 

Incurred premiums paid in period on all policies


 

 

(9,415)

 

(9,415)

 

 

(7,944)

 

(7,944)

 

 

(15,551)

 

(15,551)

Unrealised gains


 

 

 







Fair value adjustments


 

 

4,554 

 

4,554 

 

 

(89)

 

(89)

 

 

6,795 

 

6,795 

Income from life settlement portfolios


 

307 

 

 

307 

 

301 

 

 

301 

 

623 

 

 

623 

Other income


23 

23 

Net foreign exchange loss


 

(1)

 

 

(1)

 

(4)

 

 

(4)

 

 

 



______

______

______

______

______

______

_______

_______

______

Total income


329 

5,116 

5,445 

303 

4,589 

4,892 

632 

8,221 

8,853 



 

 

 







Operating expenses


 

 

 







Investment management fees

4

(810)

(743) 

(1,553)

(820)

267 

(553)

(1,640)

409 

(1,231)

Other expenses

 

(1,927)

(1,927)

(3,832)

(3,832)

(6,051)

(6,051)



______

______

______

______

______

______

_______

_______

_____

(Loss)/profit before finance costs and taxation


(2,408)

4,373 

1,965 

(4,349)

4,856 

507 

(7,059)

8,630 

1,571 

Finance costs

 

 

 

 







Interest payable


(1,102)

(1,102)

(406)

(406)

(972)

(972)



______

______

______

______

______

______

_______

_______

_____

(Loss)/profit/before taxation


(3,510)

4,373 

863 

(4,755)

4,856 

101 

(8,031)

8,630 

599 

 

 

 

 

 







Taxation




______

______

______

______

______

______

_______

_______

_____

(Loss)/profit for the period

 

(3,510)

4,373 

863 

(4,755)

4,856 

101

(8,031)

8,630 

599 



======

=====

======

======

=====

======

=======

======

=====

Return per class A share USD

6

(0.070)

0.087 

0.017 

(0.095)

0.097 

0.002 

(0.161)

0.173 

 0.012 














 

All revenue and capital items in the above statement derive from continuing operations of the Company.

 

The Company does not have any income or expense that is not included in the profit for the period and therefore the profit for the period is also the total comprehensive income for the period.

 

The total column of this statement is the Statement of Total Comprehensive Income of the Company. The supplementary revenue and capital columns are prepared in accordance with the Statement of Recommended Practice ("SORP") issued by the Association of Investment Companies ("AIC") in July 2022.

 

The notes form part of these financial statements.

 

Condensed Statement of Financial Position

as at 30 June 2023

 


 

 

 

Note

As at

30 June 2023

(unaudited)

As at

30 June

2022

(unaudited)

As at

31 December 2022

(audited)



USD'000

USD'000

USD'000

Non-current assets





Financial assets at fair value through profit or loss:




- Life settlement investments

8

73,421 

65,902 

62,742 



_______

_______

_______



73,421 

65,902 

62,742 

Current assets


 



Maturities receivable


7,518 

15,454 

7,410 

Trade and other receivables


12,180 

17 

2,051 


4,488 

6,277 

5,264 

Cash and cash equivalents


13,908 

25,902 

35,907 



_______

_______

_______



38,094 

47,650 

50,632 



_______

_______

_______

Total assets


111,515 

113,552 

113,374 



_______

_______

_______

Current liabilities


 



Other payables


(1,557)

(1,556)

(1,522)

Provision for performance fees

9

(2,182)

(2,581)

(1,939)



_______

_______

_______

Total liabilities


(3,739)

(4,137)

(3,461)



_______

_______

_______

Net assets


107,776 

109,415 

109,913 



======

======

======

Represented by


 



Capital and reserves


 



Share capital

10

498 

498 

498 

Special reserve

11

91,290 

94,290 

94,290 

Capital redemption reserve


213 

213 

213 

Capital reserve


57,727 

49,580 

53,354 

Revenue reserve


(41,952)

(35,166)

(38,442)



_______

_______

_______

Total equity attributable to ordinary Shareholders of the Company


 

107,776 

=======

 

109,415 

=======

 

109,913 

=======

Net Asset Value per share basic and diluted


 



Class A shares USD

12

2.16 

2.20 

2.21 



 



 

Registered in England and Wales with Company Registration number: 10918785

 

The notes form part of these financial statements.

 

Condensed Statement of Changes in Equity

        for the six months ended 30 June 2023

 


 

Share capital

 

Special reserve

Capital

redemption

reserve

 

Capital reserve

 

Revenue

reserve

 

 

Total


USD'000

USD'000

USD'000

USD'000

USD'000

USD'000

Six months ended 30 June 2023







Balance as at 31 December 2022

498 

94,290 

213

53,354

(38,442)

109,913 

Comprehensive income/(loss) for the period

 

 

-

4,373

(3,510)

863 

Contributions by and distributions to owners

 

 

 

 

 

 

Dividends paid in period

(3,000) 

-

-

(3,000)


____

_______

_______

______

_______

_______

Balance as at 30 June 2023

498 

91,290 

213

57,727

(41,952)

107,776 


=====

=======

=======

======

=======

=======

Of which:







Realised gains




39,813 



Unrealised gains




17,914 



Six months to 30 June 2022







Balance as at 31 December 2021

498 

94,290 

213

44,724 

(30,411)

109,314 

Comprehensive income/(loss) for the period

 

 

-

4,856 

(4,755)

101 


____

_______

_______

______

_______

_______

Balance as at 30 June 2022

498 

94,290 

213

49,580 

(35,166)

109,415 


==== 

======

=======

=====

======

======

Of which:







Realised gains




39,752 



Unrealised gains




9,828 



 

Year ended 31 December 2022







Balance as at 31 December 2021

498 

94,290 

213

44,724 

(30,411)

109,314 

Comprehensive income/(loss) for the year

-

8,630 

(8,031)

599 


_____

_______

_______

______

_______

______

Balance as at 31 December 2022

498 

94,290 

213

53,354 

(38,442)

109,913 


=====

======

=======

======

======

======

Of which:







Realised gains




40,500 



Unrealised gains




12,854 



 

The Special reserve was created as a result of the cancellation of the Share premium account following a court order issued on 18 June 2019. The Special reserve is distributable and may be used to fund purchases of the Company's own shares and to make distributions to Shareholders.

 

The revenue and realised capital reserves are also distributable reserves.

 

The notes form part of these financial statements.

 

Condensed Cash Flow Statement

for the six months ended 30 June 2023

 


 

 

 

 

Six

months ended

30 June 2023

(unaudited)

Six

months ended

30 June 2022

(unaudited)

     Year ended

31 December 2022

(audited)



USD'000

USD'000

USD'000

 

Cash flows generated from operating activities





Profit for the period


863 

101 

599 

Non-cash adjustment


 



-     movement on portfolios


(341)

3,958 

3,650 

Investment in life settlement portfolios


(11,904)

(53)

(132)

Movements in "policy advances"


1,566 

18,217 

21,764 

Interest paid


1,102 

406 

972 



 



Changes in operating assets and liabilities


 



Changes in maturities receivables


(108)

(9,249)

(1,205)

Changes in trade and other receivables


(10,129)

313 

(1,721)

Changes in premiums paid in advance


776 

248 

1,261 

Changes in other payables


35 

608 

574 

Changes in performance fee provision


243 

(267)

(909)



______

______

______

 

Net cash (outflows)/inflows from operating activities


 

(17,897)

 

14,282 

 

24,853 



 



Cash flow used in financing activities


 



Dividends paid


(3,000)

Interest paid


(1,102)

(406) 

(972)



_____

_____

______

Net cash flows used in financing activities


(4,102)

(406) 

(972)



______

______

______

Net changes in cash and cash equivalents


(21,999)

13,876 

23,881 

 


 



Cash balance at the beginning of the period


35,907 

12,026 

12,026 



______

______

______

Cash balance at the end of the period


13,908 

25,902 

35,907 

 


======

======

======

 

The notes form part of these financial statements.

 

Notes to the Condensed Financial Statements

for the six months ended 30 June 2023

 

Note 1         General information

Life Settlement Assets ("Life Settlement Assets" or the "Company") is a public company limited by shares and an investment company under section 833 of the Companies Act 2006.  It was incorporated in England and Wales on 16 August 2017 with a registration number of 10918785. The registered office of the Company is 115 Park Street, 4th Floor, London W1K 7AP.

 

The principal activity of Life Settlement Assets is to manage investments in whole and partial interests in life settlement policies issued by life insurance companies operating predominantly in the United States.

 

In May 2018, the Company received confirmation from HM Revenue & Customs of its approval as an investment trust for tax accounting periods commencing on or after 26 March 2018, subject to the Company continuing to meet the eligibility conditions contained in section 1158 of the Corporation Tax Act 2010 and the ongoing requirements in Chapter 3 of Part 2 of the Investment Trust (Approved Company) (Tax) Regulations 2011(Statutory Instrument 2011/2999).

 

The Company currently has one class of Ordinary Shares in issue, namely the A shares which principally participates in a portfolio of life settlement assets and associated liabilities, which were acquired from Acheron Portfolio Corporation (Luxembourg) SA ("APC" or the "Predecessor Company") on 26 March 2018.

 

Note 2         IFRS accounting policies

 

2.1 Basis of preparation

These condensed interim financial statements have been prepared using the same accounting policies and methods of computation as in the 2022 annual financial statements.

 

The condensed financial statements, which comprise the unaudited results of the Company have been prepared in accordance with UK adopted International Reporting Standards ("IFRS") and with the requirements of the Companies Act 2006. They have also been prepared in accordance with the SORP for investment companies issued by the AIC in July 2022, except to the extent that it conflicts with IFRS. The accounting policies are as set out in the Report and Accounts for the year ended 31 December 2022.

 

The half-year financial statements have been prepared in accordance with IAS 34 "Interim Financial Reporting".

 

The financial information contained in this Half-Yearly financial report does not constitute statutory accounts as defined by the Companies Act 2006.The financial information for the periods ended 30 June 2023 and 30 June 2022 have not been audited or reviewed by the Company's Auditor. The figures and financial information for the year ended 31 December 2022 are an extract from the latest published audited statements and do not constitute the statutory accounts for that year. Those accounts have been delivered to the Registrar of Companies and include a report of the Auditor, which was unqualified and did not contain a statement under either Section 498(2) or 498(3) of the Companies Act 2006.

 

2.2 Going concern

The Directors have made an assessment of the Company's ability to continue as a going concern and are satisfied that the Company has adequate resources to continue in operational existence for the foreseeable future (being a period of 12 months from the date these financial statements were approved). Furthermore, the Directors are not aware of any material uncertainties that may cast significant doubt upon the Company's ability to continue as a going concern, having taken into account the liquidity of the Company's investment portfolio and the Company's financial position in respect of its cash flows, liabilities from its assets and the ongoing charges, including annual premiums. Therefore, the financial statements have been prepared on the going concern basis and on the basis that approval as an investment trust will continue to be met.

 

Note 3        Gains from life settlement portfolios

When a maturity is declared, a realised capital gain or loss is recognised on the investment in the policy, calculated by deducting from the value of the maturity the initial acquisition cost and the previously unrealised fair value adjustments.

 

The amount of premiums incurred during the period is reflected as a deduction of income from life settlement portfolios. The amount of premiums paid in advance as at 30 June 2023 amounted to USD 4,488,000 (30 June 2022: USD 6,277,000, 31 December 2022: USD 5,264,000).

 

Note 4        Management fees and performance fees

 


30 June

2023

30 June

2022

31 December

2022


USD'000

USD'000

USD'000

Acheron Capital management fees

810 

820 

1,640 

Performance fees

743 

(267)

(409)


______

______

_____


1,553 

553 

1,231


=====

=====

=====

 

Under an agreement dated 26 March 2018, the Investment Manager is entitled to a management fee payable by the Trust at an annual rate of no more than 1.5% of the Net Asset Value. Management fees paid during the period amounted to USD 810,000 (30 June 2022: USD 820,000, 31 December 2022: USD 1,640,000).

 

Until 30 June 2022 the Performance fee in respect of the Trust was an amount equal to 20% of the sum of the distributions made to the holders of the Shares in the Company corresponding to the Trust, in excess of the Performance Hurdle (assessed at the time of each distribution).

 

The Performance Hurdle" was met when (from time to time) the aggregate distributions (in excess of the Catch-Up Amount) made to the holders of the corresponding Ordinary Shares compounded at 3% per annum.

 

The"Catch-Up Amount"was an amount equal to the distributions that would have been required to be made to the Predecessor Company's shareholders of the corresponding share class in order for the Accrued Performance Distributions (less, where applicable, any clawback of such Accrued Performance Distributions) to be paid (determined as at 31 December 2021), reduced by an amount equal to any distributions paid to the Predecessor Company's shareholders of the relevant share class prior to the Acquisition.

 

On 30 June 2022 the Company announced that after discussions with Acheron Capital Limited ("ACL") an agreement had been reached with ACL that once the current litigation process with one of the policy trustees has been resolved, the performance fee will be reduced from 20% as described above to 10% over the existing hurdle rate.

 

In consideration of this reduction the Board agreed to release any accrued performance fees payable to ACL held by the Company in excess of USD 1 million, as calculated at 31 January 2023, as a one-off payment. In acknowledgement of the significant work that ACL has had to perform with regard to the legal dispute over a long period, the Directors of LSA agreed to make an advance to ACL on 30 June 2022, subject to an agreed clawback mechanism, of USD 0.5 million, which was credited against the amount to be paid under the above arrangement, following the publication of the 2022 financial results.

 

Note 5        Taxation

The Company has an effective UK tax rate of 0% for the year ending 31 December 2023. The estimated effective tax rate is 0% as investment gains are exempt from tax owing to the Company's status as an investment trust and there is expected to be an excess of management expenses over taxable income.

 

The company suffers US withholding tax on income received dividends and interest. The tax charge for the period amounted to USD nil.

 

5.1 Withholding tax on matured policies

In accordance with the taxation treaty between the United States of America and the United Kingdom, withholding tax on matured policies is not due if at least 6% of the average capital stock of the main class of Shares is traded during the previous year on a recognised stock exchange. The Board believes that in the period ended 31 December 2022 the Company fulfilled this requirement.

 

Note 6        Return per share

As stated in Note 10, the share capital of the Company comprises 49,826,784 A shares.  All Shares are fully paid. Neither unpaid shares nor any kind of option are outstanding, so the basic profit/(loss) per share is also the diluted profit/(loss) per share.

 

 

Six months ended 30 June 2023

Six months ended 30 June 2022

Year ended 31 December 2022

Earnings per share:



 

Revenue return (USD'000)

(3,510)

(4,755)

(8,031)

Capital return (USD'000)

4,373 

4,856 

8,630 

Total return (USD'000)

863 

101 

599 

Weighted average number of shares in the period

 

49,826,784 

 

49,826,784 

 

49,826,784 

Income return per share (USD)

(0.070)

(0.095)

(0.161)

Capital return per share (USD)

0.087 

0.097 

0.173 

Basic and diluted total earnings per share (USD)

 

0.017 

 

0.002 

 

 0.012 





 

Note 7        Financial instruments measured at fair value

The life settlement portfolios have been classified as financial assets held at fair value through profit or loss as their performance is evaluated on a fair value basis.

 

The fair value hierarchy set out in IFRS 13 groups financial assets and liabilities into three levels based on the significant inputs used in measuring the fair value of the financial assets and liabilities.

 

The fair value hierarchy has the following levels:

-    level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities;

-    level 2: inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly (i.e as prices) or indirectly (i.e. derived from prices); and

-    level 3: inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

 

The life settlement portfolios of USD 73,421,000 (30 June 2022: USD 65,902,000, 31 December 2022: USD 62,742,000) are all classified as level 3.

 

Note 8        Financial assets held at fair value through profit or loss: Life Settlement Portfolios

 


As at 30 June

2023

USD'000

As at 30 June

2022

USD'000

As at 31 December 2022

USD'000

Movements for the period are as follows:

Opening valuation


62,742 


88,024 

 

88,024 

Acquisitions during the period

11,904 

53 

132 

Proceeds from matured policies

(14,190)

(16,266)

(27,197)

Net realised gains on policies

9,978 

12,622 

16,977 

Movements in cash from policy advances

(1,566)

(18,217)

(21,764)

Escrow rebate

(225)

6,795 

Movements in unrealised valuation

4,553 

(89)

(225)


_______

_______

______

Closing valuation

73,421 

65,902 

62,742 


=======

=======

======

 

Details at period end:

USD'000

USD'000

USD'000

Acquisition value

95,955 

91,409 

88,770 

Unrealised capital gains

17,914 

9,828 

12,854 

Policy advances

(40,448)

(35,335)

(38,882)


_______

_______

_______

Closing valuation

73,421 

65,902 

62,742 


======

======

=======

 

Distribution of the portfolio by class of Shares and by type of risk:

 

 

30 June 2023

30 June 2022

31 December 2022


USD'000

USD'000

USD'000




 

Elderly life insurance

(non-HIV) portfolio

22,082

23,770

 

22,075

HIV portfolio

51,339

42,132

40,667

 

________

________

_________

 

Balance as at 30 June 2023

73,421

65,902

62,742


=====

=====

======

 

Fair market value reflects the view of Acheron Capital Limited, the Investment Manager of the trust in which the policies of Class A are kept.

 

Note 9     Provision for performance fees

 

 

30 June 2023

30 June 2022

31 December 2022


USD'000

USD'000

USD'000




 

Provision brought forward

1,939 

2,848 

2,848 

Increase/(reduction) in provision during the period (note 4)

743 

(267)

 

(409)

Performance fee paid in the period

(500)

-  

(500)

 

________

________

_________

 

Balance as at 30 June 2023

2,182

2,581 

1,939 


=====

=====

======

 

The Performance fee does not have a fixed date for payment but can become payable immediately in the event that:

a.  a crystallisation event as set out in the Investment Management Agreement occurs; or

b. distributions to Shareholders exceed the Performance Hurdle.

 

As a result the Performance fee has been treated as a current liability.

 

As described in Note 8 on page 67 of the 2022 Annual Report, an advance of USD 500,000 was made on 30 June 2022 as a one-off payment. A further payment of USD 500,000 was advanced during the period as shown in the table above.

 

Note 10      Share Capital

At the 30 June 2023, (the Company's share capital amounts to USD 498,268 (30 June 2022: USD 498,268 31 December 2022: USD 498,268) and is represented by 49,826,784 Ordinary A shares of USD 0.01 each.

 

The issued and fully paid share capital at 30 June 2023 is comprised of 49,826,784 Class A shares.

 

Class A shares relate to specific investments determined by the Board of Directors or as the case may be, by a general meeting of Shareholders.  Each investment is undertaken for the exclusive benefit and risk of the relevant class of shares. All shares have equal voting rights.

 

Note 11      Special reserve

The Special reserve was created as a result of the cancellation of the Share premium account following a court order issued on 18 June 2019. The Special reserve is distributable and may be used to fund purchases of the Company's own shares and to make distributions to Shareholders.

 

Note 12      Net assets and net asset value per Share Class

 

The Net Asset Value (NAV) is shown below.

 

 

30 June 2023

30 June 2022

31 December 2022

Net assets (USD'000)

107,776

109,415

109,913

Number of shares

49,826,784

49,826,784

49,826,784

NAV per share (USD)

2.16

2.20

2.21

 

Note 13      Related party transactions

Related parties to the Company are the members of the Board of Directors of the Company, Compagnie Européenne de Révision S.à r.l. as Administrator who previously had a member on the Board of Directors and the Trustee of the US trust who was also previously a member of the Board of Directors.

 


30 June 2023


USD'000


 

Per income statement:

 

Trustee fees

74

Compagnie Européenne de Révision S.à r.l.

65

Directors' fees

72


 

Amounts payable per balance sheet:

 

Compagnie Européenne de Révision S.à r.l.

51

Directors' fees

14

 

 

All transactions with related parties are undertaken at arm's length.

 

 

Shares held by related parties (Directors and companies under their control)

- Michael Baines 50,000 A shares




 

Note 14      Post balance sheet events

There are no post balance sheets events to disclose.

 

COMPANY INFORMATION

 

Directors

Michael Baines - Chairman

Christopher Casey

Guner Turkmen

 

Registered Office

115 Park Street

4th Floor

London W1K 7AP

 

Auditor

BDO LLP

55 Baker Street

London

W1U 7EU

 

Trust's Investment Manager

Acheron Capital Limited

115 Park Street

4th Floor

London W1K 7AP

 

Registrars

The City Partnership (UK) Limited

The Mending Rooms

Park Valley Mills

Meltham Road

Huddersfield

HD4 7BH

 

Brokers

Shore Capital and Corporate Limited

Cassini House

57 St James Street

London

SW1A 1LD

 

Company Secretary

ISCA Administration Services Limited

Suite 8,

Bridge House

Courtenay Street

Newton Abbot

TQ12 2QS

Email: lsa@iscaadmin.co.uk

Telephone: 01392 487056

 

LEI: 2138003OL2VBXWG1BZ27

 

Website - https://www.lsaplc.com

 

Registered in England and Wales with Company Registration number: 10918785

 

Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on this announcement (or any other website) is incorporated into, or forms part of this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR UNANROVUKUAR